Jersey City Psychiatry Conference

Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.

Gus Alva, MD, DFAPA, joins Erin Crown to discuss how regional meetings, industry exchange, and emerging treatments can help clinicians avoid burnout and better serve patients.

Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.

Can EEG microstates and brain imaging predict antipsychotic response?

Reframe psychosis as upstream glutamate-GABA circuit imbalance, with dopamine disruption downstream; muscarinic drugs reduce symptoms and boost cognition.

Clinics must adapt to REMS-style models as esketamine teaches supervision and reimbursement lessons ahead of psilocybin’s potential FDA clearance.

Motivational interviewing helps clinicians address antipsychotic ambivalence, using open-ended questions to connect LAIs or clozapine to patient goals over time.

Psychedelic trials may face blinding failures; concerns around FDA safeguards, active comparators, and filmed sessions.

Ending the REMS cut the paperwork, but reimbursement that ignores clozapine’s added care demands still keeps the drug from patients who could benefit.

Psychedelic psychiatry gains momentum as clinicians weigh evidence, safety, and stigma.

Christoph U. Correll, MD, explains how a new class of muscarinic agents lowers dopamine in specific brain regions without blocking dopamine receptors.

George Grossberg, MD, reviews how accurate the first FDA-cleared Alzheimer blood test is and which patient factors can skew its results.

Anita Clayton, MD, explains why sexual dysfunction affects most patients with major depression and how it overlaps with anhedonia.

AI should take over burdensome tasks, not clinicians, and guardrails must stop decision support systems from guessing.

Blood-based biomarkers are helping clinicians move past vague dementia diagnoses, but an expert says the tests belong only after a full workup in patients with objective impairment.

Christoph U. Correll, MD, says prescriber discomfort, more than patient factors, drives low LAI use in schizophrenia, and urges clinicians to present injectables as support for autonomy.

Anita Clayton, MD, explains how anhedonia points to past trauma and to future suicide and relapse risk, and how clinicians can screen for it quickly.

Christoph Correll, MD, explains why asking "How many doses have you missed?" works better than "Are you taking your medication?" and how to address the reasons behind missed doses.

An esketamine expert reflects on 7 years of nasal spray use and asks why racemic ketamine faces none of the same rules.

Explore tailored MDD augmentation strategies, balancing antipsychotic side effects, cautious dosing in older adults, and when to consider ketamine after partial response.

Why psychiatry might miss daytime sleepiness; assess sleep debt, scale scores, and sedating meds, deprescribe wisely, and rule out sleep apnea before stimulants.

Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.